Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554786 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,216
- Enrollment target
NCT02554786 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,216 participants.
The verdict
NCT02554786, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,216 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control
Interventions
- DRUG Mometasone furoate
- DRUG Indacaterol acetate/Mometasone furoate
- DRUG Salmeterol xinafoate/fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,216 participants |
| Start Date | 2015-12-29 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554786
The ClinicalTrials.gov registry entry for NCT02554786 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Mometasone furoate is the first listed.
NCT02554786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02554786 about?
NCT02554786 is a clinical study titled "A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma". The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined ...
What is the current status of trial NCT02554786?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,216 participants. The study started on 2015-12-29. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02554786?
The interventions under investigation include: Mometasone furoate (DRUG), Indacaterol acetate/Mometasone furoate (DRUG), Salmeterol xinafoate/fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT02554786?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.